sd-com-margin.gif (1795 bytes)



Hemodynamic effects of reboxetine
in healthy male volunteers.


Denolle T, Pellizzoni C, Jannuzzo MG, Poggesi I

Biotrial Research Centre,Rennes, France.
Clin Pharmacol Ther 1999 Sep; 66(3):282-7

ABSTRACT

BACKGROUND: Reboxetine [(R,S)-2[(R,S)-alpha-(2-ethoxyphenoxy)benzyl]morpholine methanesulfonate] is a racemic compound that consists of equal proportions of R,R- and S,S-enantiomers. This study investigated the hemodynamic effects of reboxetine and the R,R-enantiomer compared with placebo in volunteers. The pharmacokinetics of reboxetine and its enantiomers were also investigated in the study. 

METHODS: Nine healthy, male volunteers received single doses of 4 mg reboxetine, 2 mg R,R-enantiomer, and placebo at weekly intervals. Reboxetine and the R,R-enantiomer were well tolerated in all volunteers. 

RESULTS: The heart rates of patients in the supine and standing positions were increased after reboxetine administration compared with the R,R-enantiomer (P < .05, except supine heart rate at 6 hours) and placebo (P < .05). Supine systolic and diastolic blood pressure was also increased by 3 4 and 1 4 mm Hg, respectively, after reboxetine compared with R,R-enantiomer (-2 4 and -4 3 mm Hg) and placebo (-4 4 and -4 4 mm Hg) administration. The systolic and diastolic blood pressure measurements for subjects while standing did not differ significantly among treatments. There was no significant difference between the maximum plasma concentration, mean time to maximum plasma concentration, plasma half-life, or area under the plasma concentration-time curve (AUC) of the R,R-enantiomer after reboxetine or R,R-enantiomer administration. The ratio of the mean AUC values for the R,R- and S,S-enantiomers was 2.1. 

CONCLUSION: These findings suggest that the S,S-enantiomer is responsible for the hemodynamic effects of reboxetine in humans. Increases in supine blood pressure after reboxetine administration may be interpreted as regression to the mean value and not caused by any treatment effect.

Back                          to order

   Reboxetine  research / abstracts

 1.   Reboxetine  role in antidepressant therapy
 2.   Reboxetine  efficacy and tolerability
 3.   Reboxetine  clinical pharmacologic profile
 4.   Reboxetine  Inhibiting noradrenaline and serotonin reuptake 
 5.   Reboxetine  and depression in the elderly
 6.   Reboxetine  with severe major depressive disorder
 7.   Reboxetine  clinical efficacy in major depression
 8.   Reboxetine  tolerability and safety for major depression
 9.   Reboxetine  comparison with fluoxetine
10.  Reboxetine  versus fluoxetine, impact on social functioning
11.  Reboxetine  versus fluoxetine, differential effects
12.  Reboxetine  prevents relapse in  major depression
13. 
Reboxetine  efficacy compared with imipramine
14.  Noradrenaline reuptake inhibition
15.  Antidepressants  noradrenergic versus serotonergic
16.  
Reboxetine  in the treatment of bulimia
17.  Reboxetine  hemodynamic effects in healthy males
18.  Reboxetine  effects of antidepressant therapy
19.  Reboxetine  place in antidepressant therapy
20.
 Reboxetine  stimulant effects in patients with narcolepsy
21.  Reboxetine  selective noradrenaline reuptake inhibitor (NARI)

Hit Counter